

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT THREE PRODUCTS OF THE INSULIN ASPART SERIES DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED BID-WINNING QUALIFICATION IN THE SPECIALISING RENEWAL IN INSULIN PROCUREMENT

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on 23 April 2024, Huisheng Biopharmaceutical Co., Ltd. (“**Huisheng Biopharmaceutical**”), a non-wholly owned subsidiary of the Group, participated in the application for National Centralized Procurement of Pharmaceuticals (specialising renewal in insulin) organized by the National Organization Joint Office for Centralized Procurement of Pharmaceuticals (the “**Joint Procurement Office**”). Three products developed by Huisheng Biopharmaceutical, including Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection, obtained bid-winning qualification in the specialising renewal in insulin procurement, and were proposed to be selected as Class A. The centralized procurement cycle for insulin is from the date of execution of the selection results to 31 December, 2027. (Note: The selected categories of the above drugs are subject to the final data released by the Joint Procurement Office).

Insulin Aspart Injection is the third-generation fast acting insulin analogue. It takes effect within 10–20 minutes after subcutaneous injection, which can better control postprandial blood glucose and reduce the risk of hypoglycemia. The injection time is more flexible and can be administered near mealtime, it can also be used for insulin pump and intravenous injection. Insulin Aspart 30/50 Injections are biphasic insulins containing 30%/50% soluble insulin aspart and 70%/50% protamine insulin aspart. They can better control fasting and post-prandial blood glucose, reduce the number of injections, and has obvious advantages in improving patients' compliance and saving medical costs. The availability of two different dosages allows clinical physicians to provide patients with more flexible and personalized treatment options based on their postprandial blood glucose levels.

The Insulin Aspart Injection, Insulin Aspart 30 Injection, and Insulin Aspart 50 Injection developed by Huisheng Biopharmaceutical were approved for launch by the National Medical Products Administration (NMPA) on 26 December, 2023. As a new entrant, this centralized procurement will benefit the sales of Huisheng Biopharmaceutical's insulin analogues, accelerate products access, increase market share, have a positive impact on enhancing Huisheng Biopharmaceutical's brand influence and future long-term development. Meanwhile, it will further improve the accessibility of insulin drugs and benefit the majority of patients in China.

ABOUT HUISHENG BIOPHARMACEUTICAL

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic medical aesthetics and pharmaceutical group, focusing on the areas of diabetes and complications. After ten years of construction and development, Huisheng Biopharmaceutical has become one of the few companies in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. The company currently has a world-class R&D team with rich experience in diabetes drug research and development. At present, it has nearly 40 products in the research product pipeline of diabetes and complications, covering a full range of second-, third-, and new-generation insulin (covering basic, premixed and quick-acting etc.), innovative drugs with the latest mechanism, such as SGLT-2 inhibitors, GLP-1 agonists, and other hypoglycemic drugs and complication drugs. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 25 April 2024

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.